Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Synthomer plc (SYYYF)
London, GB
Synthomer plc operates as a specialized chemical company, providing a broad array of solutions across various industries. The organization is structured into four primary segments: Performance Elastomers, Functional Solutions, Industrial Specialities, and Acrylate Monomers. The company offers an extensive product portfolio. This includes diverse adhesive solutions such as pressure-sensitive types, acrylic polymers and dispersions, saturants, and release coatings. For construction applications, Synthomer supplies water-based carboxylated styrene butadiene rubber, redispersible powders, flooring adhesives, and numerous additives. In the textiles sector, its offerings span impregnation binders, styrene butadiene copolymers, polymer dispersions, and butadiene-based binders. Synthomer also manufactures binders specifically for carpets, alongside synthetic binders utilized in graphic, packaging, and specialty paper coating, complemented by paper coating additives and plastic pigments. Its comprehensive range for general coating applications features binders, dispersions, water-based and solvent-borne resins, and related substances. Furthermore, the company produces foamed materials for bedding and footwear, and provides elastomeric modifiers for thermoplastics and friction components. It also delivers reinforcement resins for rubber compounds and latex for tire cords. Additional products comprise compounds and aqueous curing pastes, suitable for carpets and other uses, as well as acrylic monomers formulated to enhance the performance characteristics of polymer compounds. Antioxidant products are also part of its offerings. Synthomer is a key supplier of latices for a wide range of medical and protective uses, including examination gloves, clean rooms, food handling, chemotherapy drug handling, chemical laboratories, and medical devices and balloons. It notably provides nitrile latex, which improves the resilience and functionality of industrial and fabric-supported gloves. Beyond these, its industrial product line features liquid polybutadienes, polyvinyl alcohol suspending agents, polyvinyl acetates, thermosetting resins, butyl ethyl propanediol, and various inorganic materials. Finally, Synthomer supplies coalescing agents designed to improve the inherent qualities of coatings. Established in 1863, the company was formerly known as Yule Catto & Co. plc until it adopted its current name, Synthomer plc, in 2012. Its global headquarters are located in London, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +10.08% | +10.08% | +143.48% | +297.93% | -21.11% | -21.11% | -21.11% | -71.77% | -79.92% | -79.92% | -79.92% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals - Specialty: +4.7%-12.5% Q4'25: -9.1% (vs Q4'23)
-
EPS growth Chemicals - Specialty: +13.2%-118.2% Q4'25: +4.1% (vs Q4'23)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%-3.7% Q4'25: +9.5% (vs Q4'23)
-
EBIT margin Chemicals - Specialty: +8.8%-2.6% Q4'25: -6.2% (vs Q4'23)
-
ROIC Chemicals - Specialty: +5.6%-3.0% Q4'25: -13.0% (vs Q4'23)
-
Share dilution Chemicals - Specialty: +0.1%+0.0% Q4'25: +119.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×15.18× Q4'25: -23.79× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 6 Rev. Ana. 1 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
870.10M
est: 898.04M (-3.1%)
|
1.05B
est: 1.06B (-1.5%)
|
1.48B
est: 1.46B (+1.2%)
|
1.62B
est: 1.53B (+6.2%)
|
1.46B
est: 1.55B (-5.6%)
|
1.64B
est: 1.72B (-4.5%)
|
2.14B
est: 2.31B (-7.1%)
|
2.33B
est: 2.56B (-9.0%)
|
1.97B
est: 2.12B (-6.9%)
|
1.99B
est: 1.96B (+1.1%)
|
1.74B
est: 1.78B (-2.2%)
|
1.87B
1.85B – 1.90B
+5.1% YoY
|
1.94B
1.81B – 2.10B
+3.9% YoY
|
2.05B
1.96B – 2.15B
+5.4% YoY
|
| EBITDA |
126.40M
est: 79.28M (+59.4%)
|
202.30M
est: 93.73M (+115.8%)
|
164.60M
est: 129.09M (+27.5%)
|
179.30M
est: 134.63M (+33.2%)
|
171.80M
est: 136.49M (+25.9%)
|
151.80M
est: 152.03M (-0.2%)
|
452.50M
est: 203.68M (+122.2%)
|
142.30M
est: 226.30M (-37.1%)
|
69.50M
est: 186.97M (-62.8%)
|
83.00M
est: 149.31M (-44.4%)
|
53.90M
est: 135.21M (-60.1%)
|
142.08M
140.28M – 144.43M
+5.1% YoY
|
147.68M
137.34M – 159.84M
+3.9% YoY
|
155.66M
149.17M – 163.41M
+5.4% YoY
|
| EBIT |
80.60M
est: 35.47M (+127.2%)
|
145.40M
est: 41.94M (+246.7%)
|
96.40M
est: 57.76M (+66.9%)
|
128.40M
est: 60.24M (+113.2%)
|
111.00M
est: 61.07M (+81.8%)
|
51.10M
est: 68.02M (-24.9%)
|
398.10M
est: 91.13M (+336.9%)
|
13.20M
est: 101.25M (-87.0%)
|
-35.80M
est: 83.65M (-142.8%)
|
-13.40M
est: 55.10M (-124.3%)
|
-45.50M
est: 49.89M (-191.2%)
|
52.43M
51.76M – 53.29M
+5.1% YoY
|
54.49M
50.68M – 58.98M
+3.9% YoY
|
57.44M
55.04M – 60.30M
+5.4% YoY
|
| Net Income |
60.40M
est: 241.45M (-75.0%)
|
110.40M
est: 299.54M (-63.1%)
|
74.00M
est: 342.22M (-78.4%)
|
99.80M
est: 357.65M (-72.1%)
|
84.60M
est: 326.56M (-74.1%)
|
3.10M
est: 348.31M (-99.1%)
|
208.70M
est: 851.68M (-75.5%)
|
-32.50M
est: 280.84M (-111.6%)
|
-67.00M
est: -21.24M (-215.4%)
|
-72.60M
est: -7.74M (-838.2%)
|
-156.97M
est: -18.82M (-734.1%)
|
-643.1K
-684.8K – -608.3K
+96.6% YoY
|
10.29M
9.73M – 10.95M
+1,699.8% YoY
|
14.98M
14.17M – 15.96M
+45.6% YoY
|
| SGA |
72.10M
est: 81.32M (-11.3%)
|
94.50M
est: 96.14M (-1.7%)
|
109.60M
est: 132.41M (-17.2%)
|
113.20M
est: 138.09M (-18.0%)
|
96.80M
est: 139.99M (-30.9%)
|
179.20M
est: 155.94M (+14.9%)
|
189.60M
est: 208.91M (-9.2%)
|
165.00M
est: 232.11M (-28.9%)
|
166.60M
est: 191.77M (-13.1%)
|
198.80M
est: 135.05M (+47.2%)
|
—
est: 122.29M (-100.0%)
|
128.50M
126.88M – 130.63M
+5.1% YoY
|
133.57M
124.21M – 144.56M
+3.9% YoY
|
140.78M
134.91M – 147.79M
+5.4% YoY
|
| EPS |
1.22
est: 1.48 (-17.4%)
|
2.23
est: 1.83 (+21.7%)
|
1.50
est: 2.09 (-28.3%)
|
2.02
est: 2.19 (-7.7%)
|
1.58
est: 2.00 (-20.9%)
|
0.05
est: 2.13 (-97.5%)
|
3.56
est: 5.21 (-31.7%)
|
-0.29
est: 1.72 (-116.9%)
|
-1.84
est: -0.13 (-1,315.9%)
|
-0.42
est: -0.05 (-787.4%)
|
-0.96
est: -0.12 (-734.1%)
|
0.00
0.00 – 0.00
+96.6% YoY
|
0.06
0.06 – 0.07
+1,699.8% YoY
|
0.09
0.09 – 0.10
+45.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Willome | Chief Executive Officer & Executive Director | 2M | male |
| Lily Liu | Chief Financial Officer & Director | 1M | female |
| Faisal Tabbah | Vice President of Investor Relations | — | male |
| Jan Chalmovsky | President of Strategy and M&A | — | male |
| Rob Tupker | President of Health, Protection, Performance Materials & Asia | — | male |
| Ana Perroni Laloe | President of Coatings & Construction Solutions and EMEA | — | female |
| Stephan Lynen | President of Adhesive Solutions | — | male |
| Anant Prakash | Interim Chief Human Resources Officer, Chief Counsel & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SYYYF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
